AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02910804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/NIR fluorescent imaging-guided surgery
Study NCT00916383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg Donepezil Transdermal Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.
Study NCT00916383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.
Study NCT01578629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin
Description: Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
Study NCT03946852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Regional Perfusion
Description: Abdominal Regional Perfusion
Study NCT03915405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2455
Description: orally, once daily.
Study NCT03915405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV Administration
Study NCT01994850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Trade name: Adcetris
Study NCT02473926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity Program Intervention
Study NCT02473926 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants in the usual care arm will receive three mailings during the intervention phase.
Study NCT02028676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinically Driven Monitoring (CDM)
Description: Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
Study NCT02028676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory plus Clinical Monitoring (LCM)
Description: Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: ABC+3TC+NNRTI
Description: Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance
Description: Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance
Description: Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily ABC+3TC
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily ABC+3TC
Study NCT02028676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued cotrimoxazole prophylaxis
Study NCT02028676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopped cotrimoxazole prophylaxis
Study NCT02321033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soft drinks
Description: soft drinks with palatinose and maltodextrin
Study NCT01689779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100,000 IU cholecalciferol
Description: active drug
Study NCT01689779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator drug
Study NCT04386876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
Description: Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
Study NCT01019837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (Monovalent MF59-Adjuvanted vaccine)
Description: Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
Study NCT03656081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Ambisome®
Description: inhaled liposomal amphotericin B = inhaled LAmB
Study NCT03656081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled placebo
Description: inhaled isotonic saline
Study NCT03656081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole tablet
Study NCT03656081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole tablet
Study NCT02004977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve access to the school breakfast program
Description: Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
Study NCT03125694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
Study NCT03125694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
Study NCT03743064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Study NCT03743064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Study NCT05055310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs test
Description: plasma micRNAs concentration
Study NCT01530607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard cyclophosphamide
Description: AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
Study NCT01530607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex)
Description: Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
Study NCT02073851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGuard™HDH
Description: TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
Study NCT02387294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)
Description: vaccination
Study NCT02387294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
Description: vaccination
Study NCT03772054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalation anesthetic agent
Study NCT03772054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous anesthetic agent
Study NCT02917031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match saxagliptin
Description: 2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Study NCT05153213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger lengths
Description: Vernier caliper was used to measure finger length
Study NCT05153213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: Gillis gauge was used to measure occlusal vertical dimension
Study NCT03316950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntraGen RF
Description: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
Study NCT01578629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vehicle control
Description: vehicle control compared to Vitamin E TCT pills
Study NCT02917031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sitagliptin
Description: 50 mg or 100 mg, gray capsule
Study NCT03316950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiVA
Description: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
Study NCT02917031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match sitagliptin
Description: 50 mg or 100 mg, gray capsule
Study NCT04009655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: music selected by musician
Study NCT03147547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotional Brochure
Description: Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
Study NCT03147547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotional Brochure
Description: Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
Study NCT03147547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Testimonial Flyer
Description: Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
Study NCT03147547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teacher Endorsement
Description: Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
Study NCT03147547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Engagement Call
Description: This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
Study NCT01196546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin
Study NCT03684512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise Sessions
Description: Remote exercise sessions delivered over group video conference
Study NCT03684512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Sessions
Description: Remote exercise sessions delivered over group video conference
Study NCT03684512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Support Sessions
Description: Individual education/support/feedback sessions delivered over video chat
Study NCT03684512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Support Sessions
Description: Individual education/support/feedback sessions delivered over video chat
Study NCT03684512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook Group
Description: Facebook group for parents to provide additional support and education
Study NCT01135719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK and PRK
Description: Wavefront-guided versus wavefront-optimized LASIK or PRK.
Study NCT00279734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus + pnemococcal vaccines alone
Description: 0 mg + vaccines, Single dose, 28 days.
Study NCT00279734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + vaccines
Description: Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
Study NCT00279734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + vaccines
Description: Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
Study NCT00279734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + Vaccines
Description: parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
Study NCT03163745 — intervention group
Intervention type: PROCEDURE
Intervention: paracentesis
Description: paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
Study NCT00780078 — intervention group
Intervention type: PROCEDURE
Intervention: extubation
Description: extubation failure in patients intubated orotracheally
Study NCT03038490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABOUND
Description: an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
Study NCT01894503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant (mometasone furoate, 1350 mcg)
Description: Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablets
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets
Study NCT03316950 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo (DIVA/IntraGen combined)
Description: (DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets
Study NCT02133976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Study NCT02133976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness training
Study NCT02133976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral therapy
Study NCT02133976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Study NCT00367276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)
Description: Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
Study NCT03677297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
Study NCT03677297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
Study NCT03848767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID System
Study NCT03848767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
Study NCT03305393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Adaptiv CRT
Description: Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
Study NCT02579681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: dimethyl fumarate administered as per the arm description
Study NCT04890015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative transanal decompression tube placement
Description: Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
Study NCT03782441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Investigational Medical Device collecting spectral Raman data from tissue
Study NCT01812512 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF
Description: The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
Study NCT00521664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic platelet transfusion
Description: In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
Study NCT00521664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic platelet transfusion
Description: In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
Study NCT01137253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
Study NCT01137253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Response to intrabrachial vasodilators during IV saline infusion
Study NCT01317511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Protein drink
Study NCT01317511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Protein drink
Study NCT05643586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patient treated with 180 mg ticagrelor 12 hours before the procedure
Study NCT05643586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patient treated with 60 mg prasugrel 12 hours before the procedure
Study NCT03550768 — intervention group
Intervention type: OTHER
Intervention: MDP
Description: evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP